Henrietta M Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2233901/publications.pdf

Version: 2024-02-01

279798 2,245 38 23 citations h-index papers

g-index 41 41 41 3994 docs citations times ranked citing authors all docs

395702

33

#	Article	IF	CITATIONS
1	Brain integrity is altered by hepatic APOE $\hat{l}\mu 4$ in humanized-liver mice. Molecular Psychiatry, 2022, 27, 3533-3543.	7.9	22
2	Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE É>3/É>4 Carriers. Journal of Alzheimer's Disease, 2021, 81, 339-354.	2.6	13
3	Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 71, 1217-1231.	2.6	14
4	α-synuclein in the pathophysiology of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 23.	10.8	197
5	Associations Between APOE Variants, Tau and α-Synuclein. Advances in Experimental Medicine and Biology, 2019, 1184, 177-186.	1.6	19
6	Amyloidâ€beta 1â€40 is associated with alterations in NG2+ pericyte population exÂvivo and inÂvitro. Aging Cell, 2018, 17, e12728.	6.7	49
7	Multiple system atrophy and apolipoprotein E. Movement Disorders, 2018, 33, 647-650.	3.9	15
8	O2â€12â€06: NEUROPATHOLOGICAL FINDINGS DRIVEN BY AN APOEε4 LIVER PHENOTYPE. Alzheimer's and Dementia, 2018, 14, P652.	0.8	1
9	The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 130.	5.2	44
10	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 9.	6.2	17
11	Peripheral apoE isoform levels in cognitively normal APOE $\hat{l}\mu 3/\hat{l}\mu 4$ individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimer's Research and Therapy, 2017, 9, 5.	6.2	29
12	Apolipoprotein E lipoprotein particles inhibit amyloid- \hat{l}^2 uptake through cell surface heparan sulphate proteoglycan. Molecular Neurodegeneration, 2016, 11, 37.	10.8	45
13	O3-06-04: Apolipoprotein e affects neuronal alpha-synuclein uptake in an isoform-dependent manner. , 2015, 11, P231-P231.		1
14	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. PLoS ONE, 2015, 10, e0135458.	2.5	85
15	Involvement of Matrix Metalloproteinase-9 in Amyloid-β 1–42–Induced Shedding of the Pericyte Proteoglycan NG2. Journal of Neuropathology and Experimental Neurology, 2014, 73, 684-692.	1.7	27
16	Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2014, 40, 343-350.	2.6	16
17	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathologica, 2014, 127, 633-643.	7.7	120
18	Apolipoproteins E and J interfere with amyloidâ€beta uptake by primary human astrocytes and microglia <i>in vitro</i> . Glia, 2014, 62, 493-503.	4.9	71

#	Article	IF	CITATIONS
19	Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway. Journal of Biological Chemistry, 2014, 289, 11282-11292.	3.4	62
20	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. Journal of Proteome Research, 2014, 13, 1077-1087.	3.7	60
21	Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer's Disease or Dementia with Lewy Bodies. International Journal of Tryptophan Research, 2014, 7, IJTR.S13958.	2.3	36
22	P4-024: APOLIPOPROTEIN E: AN UNEXPLORED MODULATOR OF CELLULAR ALPHA-SYNUCLEIN UPTAKE. , 2014, 10, P791-P792.		0
23	P1-096: IRAK-4 KINASE INHIBITION REDUCES PRO-INFLAMMATORY CYTOKINE SECRETION BUT HAS NO EFFECT ON THE UPTAKE OF AMYLOID BETA BY HUMAN GLIAL CELLS. , 2014, 10, P337-P337.		O
24	P1-117: FIBRILLAR AMYLOID BETA 1-42 INCREASE YKL40 SECRETION FROM CULTURED PERICYTES. , 2014, 10, P343-P344.		0
25	NG2 cells, a new trail for Alzheimer's disease mechanisms?. Acta Neuropathologica Communications, 2013, 1, 7.	5.2	50
26	Cerebrospinal fluid inflammatory markers in Parkinson's disease – Associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity, 2013, 33, 183-189.	4.1	214
27	Low CSF Levels of Both \hat{l}_{\pm} -Synuclein and the \hat{l}_{\pm} -Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. PLoS ONE, 2013, 8, e53250.	2.5	123
28	Apolipoprotein E., 2013, , 7-23.		0
29	Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia. Current Alzheimer Research, 2012, 9, 257-266.	1.4	17
30	Cell adhesion molecules in Alzheimer's disease. Degenerative Neurological and Neuromuscular Disease, 2012, 2, 65.	1.3	30
31	Altered CSF Orexin and α-Synuclein Levels in Dementia Patients. Journal of Alzheimer's Disease, 2012, 29, 125-132.	2.6	90
32	The effect of amyloid associated proteins on the expression of genes involved in amyloid- \hat{l}^2 clearance by adult human astrocytes. Experimental Neurology, 2012, 233, 373-379.	4.1	81
33	Complement in the brain. Molecular Immunology, 2011, 48, 1592-1603.	2.2	345
34	Astrocytic Aβ1â€42 uptake is determined by Aβâ€aggregation state and the presence of amyloidâ€associated proteins. Glia, 2010, 58, 1235-1246.	4.9	139
35	Binding and uptake of Aβ1â€42 by primary human astrocytes <i>iin vitro</i> . Glia, 2009, 57, 978-988.	4.9	86
36	C4b-binding protein in Alzheimer's disease: Binding to Aβ1–42 and to dead cells. Molecular Immunology, 2008, 45, 3649-3660.	2.2	46

3

#	Article	IF	CITATIONS
37	Effects of Alzheimer's peptide and $\hat{l}\pm 1$ -antichymotrypsin on astrocyte gene expression. Neurobiology of Aging, 2007, 28, 51-61.	3.1	11
38	Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiology of Disease, 2007, 26, 27-35.	4.4	69